Evidence map›Paper›PMID 24778195›Full record

ArticleThe American journal of tropical medicine and hygiene2014

A highly conserved region between amino acids 221 and 266 of dengue virus non-structural protein 1 is a major epitope region in infected patients.

Magot Diata Omokoko, Sabar Pambudi, Supranee Phanthanawiboon, Promsin Masrinoul, Chayanee Setthapramote, Tadahiro Sasaki, Motoki Kuhara, Pongrama Ramasoota, Akifumi Yamashita, Itaru Hirai and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Non-structural protein 1 (NS1) variants from dengue virus clinical samples revealed mutations that influence NS1 production and secretion.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  4. Review
  5. Linear and Continuous Flavivirus Epitopes From Naturally Infected Humans.Frontiers in cellular and infection microbiology · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Structure-guided insights on the role of NS1 in flavivirus infection.BioEssays : news and reviews in molecular, cellular and developmental biology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Magot Diata OmokokoDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Sabar PambudiDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Supranee PhanthanawiboonDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Promsin MasrinoulDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Chayanee SetthapramoteDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Tadahiro SasakiDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Motoki KuharaDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Pongrama RamasootaDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Akifumi YamashitaDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Itaru HiraiDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Kazuyoshi IkutaDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan.
Takeshi KurosuDepartment of Virology, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan; Center of Excellence for Antibody Research (CEAR), Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand; Medical and Biological Laboratories Co., Ltd., Ina, Nagano, Japan; National Institute of Infectious Diseases, Tokyo, Japan; Laboratory of Microbiology, School of Health Sciences, Faculty of Medicine, University of the Ryukyu, Okinawa, Japan tkurosu@biken.osaka-u.ac.jp.
National Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune response to dengue virus (DENV) infection generates high levels of antibodies (Abs) against the DENV non-structural protein 1 (NS1), particularly in cases of secondary infection. Therefore, anti-NS1 Abs may play a role in severe dengue infections, possibly by interacting (directly or indirectly) with host factors or regulating virus production. If it does play a role, NS1 may contain epitopes that mimic those epitopes of host molecules. Previous attempts to map immunogenic regions within DENV-NS1 were undertaken using mouse monoclonal Abs (MAbs). The aim of this study was to characterize the epitope regions of nine anti-NS1 human monoclonal Abs (HuMAbs) derived from six patients secondarily infected with DENV-2. These anti-NS1 HuMAbs were cross-reactive with DENV-1, -2, and -3 but not DENV-4. All HuMAbs bound a common epitope region located between amino acids 221 and 266 of NS1. This study is the first report to map a DENV-NS1 epitope region using anti-DENV MAbs derived from patients.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntigens, ViralConserved SequenceDengueDengue VirusEpitopesGene ExpressionHost-Pathogen InteractionsHumansMiceMolecular Sequence DataPeptide MappingRecombinant ProteinsSerotypingAntibodies, MonoclonalAntigens, ViralEpitopesNS1 protein, dengue-1 virusNS1 protein, Dengue virus type 2NS1 protein, Dengue virus type 3Recombinant ProteinsViral Nonstructural Proteins

Identifiers

PMID24778195
PMCPMC4080554
OpenAlexW2131129000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.